Shares of GRIFOLS S A/S (NASDAQ:GRFS) saw strong trading volume on Tuesday . 1,031,009 shares traded hands during trading, an increase of 16% from the previous session’s volume of 886,688 shares.The stock last traded at $18.94 and had previously closed at $18.47.
A number of analysts recently issued reports on the company. BidaskClub lowered GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. Zacks Investment Research lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Monday, April 1st. Berenberg Bank lowered GRIFOLS S A/S from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Finally, Morgan Stanley decreased their target price on GRIFOLS S A/S from $20.00 to $19.00 and set an “underweight” rating on the stock in a research note on Wednesday, January 2nd. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $21.00.
The company has a market capitalization of $12.78 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.33 and a beta of 1.07. The company has a quick ratio of 1.22, a current ratio of 2.77 and a debt-to-equity ratio of 1.30.
A number of hedge funds and other institutional investors have recently made changes to their positions in GRFS. Advisors Asset Management Inc. increased its stake in GRIFOLS S A/S by 58.0% in the 4th quarter. Advisors Asset Management Inc. now owns 3,629 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 1,332 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of GRIFOLS S A/S by 45.3% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,770 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,799 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of GRIFOLS S A/S during the 4th quarter valued at about $144,000. Mercer Global Advisors Inc. ADV bought a new position in shares of GRIFOLS S A/S during the 1st quarter valued at about $240,000. Finally, Amundi Pioneer Asset Management Inc. bought a new position in shares of GRIFOLS S A/S during the 4th quarter valued at about $242,000. Institutional investors and hedge funds own 19.96% of the company’s stock.
GRIFOLS S A/S Company Profile (NASDAQ:GRFS)
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Article: Cost of Equity For A Business, Investors
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.